Item 7.01. Regulation FD Disclosure.
On October 7, 2020, VYNE Therapeutics Inc. (the "Company") issued a press
release entitled "VYNE Therapeutics Announces Covered Status for ZILXI™
(minocycline) with Express Scripts." A copy of the press release is attached as
Exhibit 99.1 to this report.
In addition, on October 5, 2020, Patrick LePore, a member of the Company's Board
of Directors, entered into a stock trading plan in accordance with Rule 10b5-1
of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the
Company's insider trading policy to purchase shares of the Company's common
stock. Under the plan, Mr. LePore intends to purchase 200,000 shares of the
Company's common stock at prevailing market prices through his broker over the
next twelve months, subject to the terms of the plan. Transactions under Mr.
LePore's 10b5-1 plan will be reported to the Securities and Exchange Commission
in accordance with applicable securities laws, rules and regulations.
The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and
shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or
otherwise subject to the liability of that section, nor shall they be deemed
incorporated by reference in any of the Company's filings under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
The following exhibit is furnished herewith.
Exhibit No. Description
99.1 Press Release, dated October 7, 2020.
104 Cover Page Interactive Date File (embedded within the Inline
© Edgar Online, source Glimpses